{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:05:18Z","timestamp":1789247118865,"version":"build-2803163510"},"reference-count":29,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/rkwu3795","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:02:18Z","timestamp":1767682938000},"page":"5364-5373","source":"Crossref","is-referenced-by-count":1,"title":["Selinexor combined with R-GDP as salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.62347","volume":"15","author":[{"given":"Shiyu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the national cancer data base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ and Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the national cancer data base from 1998 to 2011. Am J Hematol 2015; 90: 790-795.","journal-title":"Am J Hematol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","unstructured":"Sehn LH and Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021; 384: 842-858.","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY and Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130: 1800-1808.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma","volume":"333","author":"Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540-1545.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"12","volume":"32","author":"Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE and Shepherd LE. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014; 32: 3490-3496.","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH and Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190.","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","unstructured":"Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S and Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol 2014; 7: 85.","journal-title":"J Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","unstructured":"Tan DS, Bedard PL, Kuruvilla J, Siu LL and Razak AR. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov 2014; 4: 527-537.","journal-title":"Cancer Discov"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E and Canales MA. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020; 7: e511-e522.","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"6621","DOI":"10.1182\/blood-2022-157496","article-title":"Selinexor in combination with R-GDP for patients with relapsed\/refractory B-cell lymphoma: final results of 18 patients treated at RP2D of selinexor in the SELINDA phase Ib Lysa study","volume":"140","author":"Maerevoet","year":"2022","unstructured":"Maerevoet M, Casasnovas O, Cartron G, Morschhauser F, Thieblemont C, Bouabdallah K, Feugier P, Szablewski V, Becker S and Tilly H. Selinexor in combination with R-GDP for patients with relapsed\/refractory B-cell lymphoma: final results of 18 patients treated at RP2D of selinexor in the SELINDA phase Ib Lysa study. Blood 2022; 140: 6621-6622.","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1182\/blood-2023-180535","article-title":"Update of swatch study: selinxor combined with Lenalidomide and Rituximab (R2) in adults with diffuse large B cell lymphoma (DLBCL) and indolent non-Hodgkin’s lymphoma (iNHL)","volume":"142","author":"Wang","year":"2023","unstructured":"Wang L, Li ZM, Zhang LN, Zhang LL, Mei J and Zhao WL. Update of swatch study: selinxor combined with Lenalidomide and Rituximab (R2) in adults with diffuse large B cell lymphoma (DLBCL) and indolent non-Hodgkin’s lymphoma (iNHL). Blood 2023; 142: 6235.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/00007890-200202270-00038","article-title":"Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy","volume":"73","author":"Kollmar","year":"2002","unstructured":"Kollmar O, Becker S, Schilling MK and Maurer CA. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy. Transplantation 2002; 73: 669-670.","journal-title":"Transplantation"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ram R, Ben-Bassat I, Shpilberg O, Polliack A and Raanani P. The late adverse events of rituximab therapy--rare but there! Leuk Lymphoma 2009; 50: 1083-1095.","DOI":"10.1080\/10428190902934944"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E and Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-3068.","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/cncr.20587","article-title":"Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)","volume":"101","author":"Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J and Meyer R. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101: 1835-1842.","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/bjh.19555","article-title":"17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed\/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP","volume":"205","author":"Stewart","year":"2024","unstructured":"Stewart DA, Kuruvilla J, Lee D, Dudebout JJ, Chua N, Larouche JF, Baetz T, Shafey M, Abdel-Samad N, Robinson S, Fleury I, Fraser G, Skrabek P, Kukreti V, Kelly J, Hay AE, Shepherd LE, Chen BE and Crump M. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed\/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP. Br J Haematol 2024; 205: 881-890.","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","unstructured":"Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O’Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J and Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-3688.","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12185-011-0884-x","article-title":"An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma","volume":"94","author":"Miura","year":"2011","unstructured":"Miura K, Takei K, Kobayashi S, Kiso S, Hirabayashi Y, Hojo A, Kodaira H, Yagi M, Kurita D, Kobayashi Y, Tanaka T, Iriyama N, Hatta Y, Kura Y, Yamazaki T, Sawada U and Takeuchi J. An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma. Int J Hematol 2011; 94: 90-96.","journal-title":"Int J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E and Caballero MD; Grupo Español de Linfomas\/Trasplante Autólogo de Médula Osea (GEL\/TAMO Cooperative Group). R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study. Haematologica 2008; 93: 1829-1836.","DOI":"10.3324\/haematol.13440"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Herrera AF, Chen L, Crombie JL, Cohen JB, Advani RH, LaCasce AS, Popplewell LL, Puverel S, Peters L, Daniels S, Godfrey J, Shouse G, Mei M, Kambhampati S, Budde LE, Nikolaenko L, Rosen ST, Kwak LW, Forman SJ and Matasar MJ Polatuzumab vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood 2022; 140: 1065-1067.","DOI":"10.1182\/blood-2022-165699"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1182\/blood-2022-158278","article-title":"Subcutaneous Epcoritamab + R-Dhax\/C in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplant: updated phase 1\/2 results","volume":"140","author":"Abrisqueta","year":"2022","unstructured":"Abrisqueta P, Cordoba R, Falchi L, Vos SD, Nijland M, Offner F, Wu J, Bykhovski I, Wang L, Rana A and Phillips T. Subcutaneous Epcoritamab + R-Dhax\/C in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplant: updated phase 1\/2 results. Blood 2022; 140: 1068-1069.","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1182\/blood-2024-198452","article-title":"Glofitamab in combination with rituximab plus ifosfamide, carboplatin, and etoposide shows favorable efficacy and manageable safety in patients with relapsed or refractory diffuse large b-cell lymphoma, eligible for stem cell transplant or chimeric antigen receptor T-cell therapy: results from a phase Ib study","volume":"144","author":"Diefenbach","year":"2024","unstructured":"Diefenbach CS, Caimi PF, Saba NS, Vargas Madueno F, Hamadani M, Fayad LE, Riedell PA, Gillis-Smith A, Simko S, Orellana-Noia V, Filippou-Frye M, Kapp AV, Relf J, Lundberg L and Pinter-Brown LC. Glofitamab in combination with rituximab plus ifosfamide, carboplatin, and etoposide shows favorable efficacy and manageable safety in patients with relapsed or refractory diffuse large b-cell lymphoma, eligible for stem cell transplant or chimeric antigen receptor T-cell therapy: results from a phase Ib study. Blood 2024; 144: 987.","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma","volume":"17","author":"CH","year":"1999","unstructured":"Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O’Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD and Zelenetz AD. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17: 3776-3785.","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1046\/j.1365-2141.1996.437976.x","article-title":"The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin’s lymphoma: identification of major prognostic groups","volume":"92","author":"Prince","year":"1996","unstructured":"Prince HM, Imrie K, Crump M, Stewart AK, Girouard C, Colwill R, Brandwein J, Tsang RW, Scott JG, Sutton DM, Pantalony D, Carstairs K, Sutcliffe SB and Keating A. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin’s lymphoma: identification of major prognostic groups. Br J Haematol 1996; 92: 880-889.","journal-title":"Br J Haematol"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U and Johnston PB. Autologous stem cell transplant in fit patients with late relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Transplant Cell Ther 2024; 30: 1001.e1001-1001.e1012.","DOI":"10.1016\/j.jtct.2024.07.008"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Boardman AP and Salles G. CAR T-cell therapy in large B cell lymphoma. Hematol Oncol 2023; 41 Suppl 1: 112-118.","DOI":"10.1002\/hon.3153"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K and Kamdar M. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023; 141: 1675-1684.","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"FL","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI and Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022; 386: 640-654.","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma","volume":"29","author":"Epperla","year":"2023","unstructured":"Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA and Hamadani M. ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma. Transplant Cell Ther 2023; 29: 548-555.","journal-title":"Transplant Cell Ther"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:38:49Z","timestamp":1768977529000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/12\/ajcr0168608.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/rkwu3795","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}